more news issued by the company via their web site:(none of these stories are hitting the newswires due to cost-cutting by the company, so nobody is really noticing the company right now.)
World Kidney Day / Groundhog Day? GenoMed Can Still Prevent Most Kidney Failure
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—March 12, 2009—GenoMed® (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company, announced again today, World Kidney Day, that it has found drug "recipes" to prevent most kidney failure.
The method was published in a peer-reviewed medical journal in September, 2002, but has received little publicity since.
GenoMed's approach reversed early kidney failure in white, black, and Hispanic patients with diabetes and high blood pressure. Diabetes and high blood pressure cause 90% of kidney failure in the US. Kidney failure affects people of color disproportionately more than whites.
The Centers for Medicaid and Medicare (CMS) currently pay $35 billion annually for kidney dialysis and transplantation. A typical dialysis patient costs $100,000 a year, and lives for less than 3 years on dialysis. When GenoMed's CEO, Dr. David Moskowitz, briefed CMS about his paper in 2004, the Medical Director and his staff at CMS had no interest. Neither did the National Institutes of Health, nor any non-profit kidney association, such as the National Kidney Foundation.
Said Dr. Moskowitz, "In medical school, we were exhorted to find cures. I wouldn't have believed it then if somebody had told me there was no point in finding a cure because news of the cure would be suppressed. Yet that's exactly what's happened for the past six and a half years."
Dr. Moskowitz continued, "Medicine, like any business, prefers the status quo. Small financial disruptions can be tolerated, like curing polio and TB in the 1950s. Other than the staff of the polio wards and the TB sanitaria, nobody in medicine was hurt financially. But eliminating 90% of a $35 billion a year industry is another thing altogether. Nobody in healthcare wants their budget or their revenues cut."
Dr. Moskowitz ended by saying, "If the President is to succeed at healthcare reform, he needs to realize this fundamental truth about the healthcare system: it will resist any attempt to reform it. But healthcare's days are numbered. GenoMed is leading the revolution towards preventive molecular medicine."
About GenoMed
In addition to avoiding dialysis in chronic kidney failure, GenoMed was also awarded a patent (6,998,404 B2) to treat acute kidney failure without dialysis. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5-10 years. Patients with diabetes, hypertension, or emphysema are encouraged to contact Dr. Moskowitz about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
